 These unprecedented and promising results from the phase II SPRINT trial, led, first in 2018, both the Food and Drug Administration (FDA) and the European Medicines Agency to grant Selumetinib an "Orphan Drug Status" for the treatment of neurofibromatosis type 1, and then, a few months later in 2019, FDA to grant a "Breakthrough Therapy Designation" to the inhibitor.The "Drosophila melanogaster" ortholog gene of human NF1 (dNF1) has been identified and cloned in 1997.The gene is slightly more compact than its human counterpart but still remains one of the largest genes of the fly genome.